Mipasetamab (Anti-AXL / UFO)

Synonyms: null

Catalog No.A2774 Purity:≥99%

Mipasetamab (Anti-AXL / UFO) is a human monoclonal IgG1κ antibody targeting AXL, a tyrosine kinase receptor, and an TAM receptor, which involves the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). MW: 145.78 kD.

Purity & Quality Control

≥99

Choose Selective Axl Inhibitors

Name	Citation	Axl	Others
BMS-777607	57	++++	RON,Met,Tyro3
Bemcentinib (R428)	124	++
XL092	0	+++	VEGFR2,MER,MET
UNC2025	7	+++	FLT3,Mer,TrkA
Ningetinib	0	++++	VEGFR2,c-Met
Tamnorzatinib (ONO-7475)	3	++++	Mer,FLT3
RU-301	0	+
Sitravatinib (MGCD516)	4	++++	DDR2,EPHA3,Mer
CEP-40783 (RXDX-106)	6	+++	c-Met,Tyro3,MER
S49076	1	+++	Met,Mer,FGFR3
Merestinib (LY2801653)	10	+++	DDR1,Met,DDR2
SGI-7079	3	+	YES,Mer,Met
UNC2025 HCl	9	++	Mer,FLT3,Tyro3
Dubermatinib(TP-0903)	17	+
NPS-1034	3	++	Met
LDC1267	9	+	Mer,Tyro3
PF-07265807	✔	Mer

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Mipasetamab (Anti-AXL / UFO) is a human monoclonal IgG1κ antibody targeting AXL, a tyrosine kinase receptor, and an TAM receptor, which involves the synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). MW: 145.78 kD.

References
[1] Zammarchi F, et al. Mol Cancer Ther. 2022;21(4):582-593.

References

[1] Zammarchi F, et al. Mol Cancer Ther. 2022;21(4):582-593.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2361055-48-1
Molecular Weight	145.78
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.